Diaceutics Plc · LSE:DXRX
Diaceutics — Investor Presentation (February 2024)
19 slides from Diaceutics's investor presentation, February 2024
Slide 1: Helping pharma find patients
Helping pharma find patients Corporate Overview – February 2024 Ryan Keeling | Chief Executive Officer | [email protected] Nick Roberts | Chief Financial Officer | [email protected] © copyright Diaceutics 2024 Permission must be sought from Diaceutics if you wish to reproduce any
Slide 2: Disclaimer and forward-looking statements
Disclaimer and forward-looking statements Disclaimer : The information provided in this presentation is for the sole use of those attending the presentation This presentation has been prepared by Diaceutics the (“Company”). “Presentation” means this document, any oral presentation, any question and
Slide 3: We help pharma find patients: 3 unique assets
We help pharma find patients: 3 unique assets 1. Lab network 2. Data 3. DXRX Platform Global network of World’s largest repository of World’s first diagnostic 900 labs healthcare data commercialisation platform for precision medicine Pharma Labs Physicians Patients • ID patients daily • ↑ Diagnostic
Slide 4: What is precision medicine?
What is precision medicine? Traditional medicine • Radiation • Chemotherapy Precision medicine (PM) is the tailoring of medical treatment • Surgery to the individual characteristics of each patient – a patient’s unique genetic profile makes them susceptible to certain diseases and can influence whic
Slide 5: The diagnostic challenge: Precision medicine practice gaps
The diagnostic challenge: Precision medicine practice gaps The healthcare Physicians ‘Practice Gaps’ Pharma are Our diagnostic eco-system can’t link are materially losing out on commercialization hasn’t caught patients to the impacting patient potential platform – DXRX – up with right drug. quality
Slide 6: 18+ Years of performance & growth
18+ Years of performance & growth 2005-2010 2011-2015 2016-2019 2020-2023 • Co-founded by • 1st implementation • Exporter of the Year • Launch DXRX - The Diagnostic Peter & Ryan service Network® • Introduced AI Keeling • Lab service network • IPO on AIM • New Diaceutics HQ • Diaceutics • Launched PM
Slide 7: Diaceutics - Today and the future
Diaceutics - Today and the future 161 50 people therapy brands 2024 + • Capture significant & growing market opportunity 15 4 • Continue to scale rapidly & profitably enterprise-wide countries engagements • Enterprise-wide engagements to drive momentum • Focus on recurring revenue • Deploy enhanced
Slide 8: Significant & growing market opportunity
Helping pharma Significant & growing market opportunity find patients Global pharma rapidly shifting to precision medicine to find more patients, capture lost revenue and increase profitability Growth driven by customer success Strong competitive Compelling Financial Demonstrable track advantage val
Slide 9: The DXRX solution
The DXRX solution DXRX Platform solutions Advisory Services Insights Solutions Engagement Solutions Consulting services: Real-world patient data products: Communication channel products: • PM pharma consulting • Lab Segmentation • Commercialization strategy • Lab Engage and planning • Physician Segm
Slide 10: Our IP- DXRX transforming data into insights
Our IP- DXRX transforming data into insights Diaceutics Diagnostic Product Data Deductive Insights Pathways Insights Solutions Engagement Solutions (DDPs) Patient histories Expert AI / ML Insight Solutions labelling Mulitple (Data) Testing/ diseases treatment Lab Raw data Stage of Results/ Segmentat
Slide 11: What we do- A DXRX Signal case study
What we do- A DXRX Signal case study The challenge 494 labs supplying weekly data Patient lead generation YTD 2023 Week 1 Due to the rarity of certain Week 2 biomarkers, the identification of Week 3 Week 4 eligible patients is challenging. Week 5 Week 6 It was critical for the client to Week 7 Week
Slide 12: DXRX Signal - Patient intervention points
DXRX Signal - Patient intervention points 12 © copyright Diaceutics 2024 Permission must be sought from Diaceutics if you wish to reproduce any part of this presentation Permission must be sought from Diaceutics if you wish to reproduce any part of this presentation
Slide 13: Industry leaders in diagnostic commercialisation
Industry leaders in diagnostic commercialisation PETER KEELING JILLIAN BEGGS KELLY WILLIAMS Founder Chief Commercial Officer VP Insight Solutions RYAN KEELING DAVID BROWN ARRAN RUTLEDGE Chief Executive Officer VP Operations VP of Finance NICK ROBERTS SARAH BONDI SHILPA HARIDAS Chief Financial Office
Slide 14: Strategy update
Strategy update Enrich data and Accelerate growth Invest in platform Transform our platform products and engagement of scale and customer lab network capability experience and service • Daily Signal launched • Laboratory network • Investment in • Listening to our • Tokenisation of data and platform-
Slide 15: Financial strength
Financial strength Ability to deliver exceptionally high margins through operational leverage Revenue CAGR of 23% over past 3 years >50% of revenues are now recurring in nature and growing – good order book visibility Enterprise-wide engagements with blue-chip customers will drive momentum Strong ba
Slide 16: FY 2023 - Financial dashboard
FY 2023 - Financial dashboard Revenue Recurring revenue Order book value Cash & equivalents £23.7m >50% £26.6m £16.7m Up 22% Driven by DXRX £12.3m to be In line with 19% constant platform products recognised in FY 2024 investment plans currency growth or platform-based solutions from £7.5m from 35%
Slide 17: FY 2023 - Operational dashboard
FY 2023 - Operational dashboard 4 enterprise-wide 93% contract 69 customer >33 therapies with engagements volume renewal therapies lifetime revenues TCV of $20.1m rate over $1 million Up from nil 30+ therapies with Up 23% from Up from 26 DXRX Signal 56 in FY 2022 Launch of enriched dedicated custome
Slide 18: Outlook & future growth
Outlook & future growth • Capture significant & growing market opportunity • Continue to scale rapidly & profitably • Enterprise-wide engagements to drive momentum • Focus on recurring revenue • Deploy enhanced technologies across DXRX platform • Grow beyond pharma - biotech, life science & payers A
Slide 19: Team & contacts
Team & contacts Ryan Keeling Nick Roberts Chief Executive Officer Chief Financial Officer [email protected] Christian Glennie | Stifel | [email protected] Hayley Palmer | Canaccord Genuity | [email protected] Julie Simmonds | Panmure Gordon | [email protected] Natali